The Food and Drug Administration has told the makers of Synthroid, the third most frequently prescribed drug in the U.S., that the medicine has a “history of problems” and cannot be recognized as “safe and effective.”The agency’s statements raise the possibility that the 40-year-old drug, which has never been officially approved for use by the Read more about Abbott’s Synthroid Faces Removal[…]
Orion Pharma has entered into a licensing agreement with the Population Council, an international, nonprofit U.S.-based organization, providing Orion Pharma worldwide exclusive rights to develop, manufacture, market, sell, and sublicense the synthetic progestin, Nestorone, for hormone replacement therapy (HRT) in transdermal dosage forms other than the patch. Nestorone is a new chemical entity that is Read more about Orion Pharma Gains Rights To Nestorone In Transdermal Gels[…]
Berlex Laboratories has announced FDA approval of their new low-dose, monophasic oral contraceptive, the first to contain the unique progestin, drospirenone. Drospirenone is different from the progestins currently available in other oral contraceptives. As an analogue of spironolactone, which is widely used by Ob/Gyns for many women, drospirenone exhibits antimineralocorticoid activity which influences the regulation Read more about FDA Approves Progestin Contraceptive Yasmin[…]